Lexicon Pharmaceuticals Inc logo

LXRX - Lexicon Pharmaceuticals Inc Share Price

$3.3 0.1  3.1%

Last Trade - 21/10/19

Sector
Healthcare
Size
Small Cap
Market Cap £262.2m
Enterprise Value £369.4m
Revenue £33.3m
Position in Universe 3277th / 6411
Bullish
Bearish
Unlock LXRX Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

LXRX Revenue Unlock LXRX Revenue

Net Income

LXRX Net Income Unlock LXRX Revenue

Normalised EPS

LXRX Normalised EPS Unlock LXRX Revenue

PE Ratio Range

LXRX PE Ratio Range Unlock LXRX Revenue

Dividend Yield Range

LXRX Dividend Yield Range Unlock LXRX Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2019
31st Dec 2020
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
LXRX EPS Forecasts Unlock LXRX Revenue
Profile Summary

Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of breakthrough treatments for human disease. Its drug programs include XERMELO (telotristat ethyl), sotagliflozin, LX2761 and LX9211. It also has a number of additional compounds into various stages of clinical and preclinical development. XERMELO is an orally-delivered small molecule compound approved by the Food and Drug Administration (FDA) for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog (SSA) therapy in adults inadequately controlled by SSA therapy. It is developing sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for type 1 and type 2 diabetes mellitus. LX2761 is an orally-delivered small molecule compound that it is developing for the treatment of diabetes. LX9211 is an orally-delivered small molecule compound that the Company is developing for the treatment of neuropathic pain.

Directors
Last Annual December 31st, 2018
Last Interim June 30th, 2019
Incorporated July 7, 1995
Public Since April 7, 2000
No. of Shareholders: 324
No. of Employees: 202
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Global Select Market
Shares in Issue 106,271,927
Free Float (0.0%)
Eligible for
ISAs
SIPPs
LXRX Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for LXRX
Upcoming Events for LXRX
Wednesday 30th October, 2019 Estimate
Q3 2019 Lexicon Pharmaceuticals Inc Earnings Release
Wednesday 11th March, 2020 Estimate
Q4 2019 Lexicon Pharmaceuticals Inc Earnings Release
Similar to LXRX
© Stockopedia 2019, Thomson Reuters, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.